The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
FDA cleared 2 new methods for administering mepolizumab (Nucala, GlaxoSmithKline): autoinjector and a pre-filled safety syringe. They are indicated
for patients or caregivers to administer once every 4 weeks.
Related: Biologic Gets Asthma Indication
The approval gives healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate, GlaxoSmithKline said in a statement.
The original lyophilised powder version remains available for administration by a healthcare professional.
“People living with conditions like severe asthma often struggle to control their day-to-day symptoms, making routine activities like attending healthcare appointments a challenge. Empowering patients to take their medicines at home is an approach that has been successful in other chronic diseases such as diabetes and rheumatoid arthritis,” said Tonya Winders, president of the Global Allergy and Asthma Patient Platform (GAAPP), in the GlaxoSmithKline statement. “GAAPP welcomes this approval for Nucala so it can be administered in a doctor’s office or in the convenience of a patient’s home.”
Related: FDA Clears Novel Device For Severe Emphysema
The approval is supported by positive patient exaperience data from two open-label, single-arm, phase 3a studies evaluating the real-world use of Nucala administered via the new options in-clinic and at home by patients with SEA, or by their caregivers.
Both studies showed patients were able to successfully self-administer treatment with both the autoinjector and pre-filled syringe after appropriate training (89% to 95% and 100% respectively). In addition, the majority of patients preferred at home self-administration options compared to in-clinic administration.
A separate open-label, parallel-group, single-dose study confirmed that the pharmacokinetic and pharmacodynamic profile of Nucala administered via pre-filled syringe or autoinjector was comparable to the originally approved lyophilised formulation, according to GlaxoSmithKline.
Read more: FDA Clears Subcutaneous Injectable To Treat Breast Cancer
Remote Care Advancement for Heart Failure, COPD and Diabetes Patients
February 24th 2021In this week's episode of Tuning In to the C-Suite podcast, MHE's Briana Contreras spoke with Dr. Rob Kowal, chief medical officer of the Cardiac Rhythm and Heart Failure division at Medtronic. The two discussed how remote monitoring and IoT is changing healthcare and how remote technology is also gaining a wide-spread adoption to monitor patients at home who have chronic conditions like heart failure, chronic obstructive pulmonary disease and diabetes.
Listen
Data From Long COVID Study Could Shed Light on Pulmonary Fibrosis Causes and Treatment
November 4th 2024Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More